In the recent updates,
Quest Diagnostics (DGX) is emerging as a strong player in the biotech industry. Its new
Pharmacogenomic Test is reshaping its investment status while the launch of
Advanced Pharmacogenomics (PGx) offering signifies a substantial breakthrough. The company's expansion into
Precision Medicine and Pharmacogenomics highlights their strategic positioning in the growing market. Further, the collaboration with
Corewell Health for a lab venture in Michigan and completion of the acquisition of clinical testing assets from
Fresenius Medical Care indicate strong growth plans. Additionally, the company's partnership with
Google Cloud to streamline data and personalize customer experiences using generative AI adds an innovation aspect. Financially, the company demonstrated strong Q2 2025 earnings with significant revenue growth. The FDA granted a breakthrough device designation for their
Haystack MRD Circulating Tumor DNA Test. Amid these updates, DGX stock hit an all-time high at 182.43 USD, gaining strong traction among investors.
Quest Diagnostics DGX News Analytics from Tue, 03 Dec 2024 08:00:00 GMT to Sat, 06 Sep 2025 14:19:53 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 6
